Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure

Executive Summary

Termination of osteoporosis drug odanacatib due to stroke risk means a loss for Merck in reliving the glory days of branded Fosamax.

Advertisement

Related Content

Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?
Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck
Inflammation A Clue Left In ACCELERATE CETP Wreckage
Merck's Anacetrapib Survives Futility Exam, But Will It Pass Final Test?
ASBMR 2014: Four bone drug updates, including Merck's odanacatib
Merck sleep aid Belsomra OK'd by FDA
Merck Eyes Primary Care Opportunities Despite Challenges

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel